Fig. 3From: Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysisForest plot for the meta-analysis of risk of bleeding in patients assigned to prasugrel or ticagrelor as compared with clopidogrel on the basis of GPIBack to article page